<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9712">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05691881</url>
  </required_header>
  <id_info>
    <org_study_id>LS2020004</org_study_id>
    <nct_id>NCT05691881</nct_id>
  </id_info>
  <brief_title>68Ga-labeled NY105 PET Imaging in Patients</brief_title>
  <official_title>68Ga-labeled NY105 PET Imaging in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Jiangnan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY105&#xD;
      PET Imaging in patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of tissue distribution of 68Ga-NY105</measure>
    <time_frame>1 day</time_frame>
    <description>Biodistribution of 68Ga-NY105 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-NY105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-NY105</intervention_name>
    <description>Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105</description>
    <arm_group_label>68Ga-NY105</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily signed informed consent;&#xD;
&#xD;
          2. Age 18-75, male or female;&#xD;
&#xD;
          3. Patients diagnosed with cancer confirmed by histopathology or cytology;&#xD;
&#xD;
          4. At least one measurable solid lesion has been examined according RECIST1.1 standard;&#xD;
&#xD;
          5. ECOG score 0~3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recovery from major trauma (including surgery) within 4 weeks prior to study&#xD;
             treatment;&#xD;
&#xD;
          2. Patients with systemic or locally severe infections, or other serious coexisting&#xD;
             diseases;&#xD;
&#xD;
          3. Patients with abnormal immune function or who have recently used immunosuppressive or&#xD;
             potentiating agents including various vaccines;&#xD;
&#xD;
          4. Patients with autoimmune diseases, including rheumatoid arthritis;&#xD;
&#xD;
          5. Inadequate control of arrhythmias, including atrial fibrillation;&#xD;
&#xD;
          6. Uncontrolled hypertension;&#xD;
&#xD;
          7. Patients with allergies or allergies to any component of the imaging agent or&#xD;
             antibody;&#xD;
&#xD;
          8. Patients who cannot undergo PET/CT imaging scan;&#xD;
&#xD;
          9. Syphilis, HBV, HCV, or HIV positive subjects;&#xD;
&#xD;
         10. Male and female subjects of reproductive age cannot take effective contraceptive&#xD;
             measures;&#xD;
&#xD;
         11. Pregnant or lactating women;&#xD;
&#xD;
         12. Patients with a history of mental illness or related conditions;&#xD;
&#xD;
         13. Other subjects considered unsuitable by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjing Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Jiangnan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjing Yu</last_name>
    <phone>15312238622</phone>
    <email>ycj_wxd1978@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunjing Yu</last_name>
      <phone>15312238622</phone>
      <email>ycj_wxd1978@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>January 11, 2023</last_update_submitted>
  <last_update_submitted_qc>January 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Hospital of Jiangnan University</investigator_affiliation>
    <investigator_full_name>Chunjing Yu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

